The Epidemiology of Pendred Syndrome and Viable Treatment Therapies
DOI:
https://doi.org/10.58445/rars.886Keywords:
Pendred Syndrome, Cochlear implants, hearing disorderAbstract
Pendred Syndrome is a form of syndromic hearing loss characterized by sensorineural hearing loss, inner ear malformations, and irregularities of the thyroid and temporal bone. Pendred Syndrome is predominantly caused by genetic mutations in SLC26A4, but FOXL1 and KCNJ10 may also be involved. Treatment involves using cochlear implantation to target hearing loss, which is associated with positive outcomes. Treatments for other effects of Pendred Syndrome include anticholinergics or benzodiazepines to treat vertigo and levothyroxine for hypothyroid patients. This review compiles the most recent information about Pendred Syndrome, and it provides a summary of the etiology, pathogenesis, and physical effects of the disorder.
References
Anna M. H. Korver, Richard J. H. Smith, and Guy Van Camp, “Congenital hearing loss,” Jan. 2017, [Online]. Available: https://www.nature.com/articles/nrdp201694#citeas
Geoffrey Casazza and Jeremy D. Meier, “Evaluation and management of syndromic congenital hearing loss,” Oct. 2017, [Online]. Available: https://journals.lww.com/co-otolaryngology/abstract/2017/10000/evaluation_and_management_of_syndromic_congenital.9.aspx
Samantha B. Allen and Julie Goldman, “Syndromic Sensorineural Hearing Loss,” Jul. 2023, [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK526088/
Y. Soares de Lima et al., “Syndromic hearing loss molecular diagnosis: Application of massive parallel sequencing,” Hear. Res., vol. 370, pp. 181–188, Dec. 2018, doi: 10.1016/j.heares.2018.10.008.
M. Ideura et al., “Comprehensive analysis of syndromic hearing loss patients in Japan,” Sci. Rep., vol. 9, no. 1, p. 11976, Aug. 2019, doi: 10.1038/s41598-019-47141-4.
J.-L. Wémeau and P. Kopp, “Pendred syndrome,” SI Genet. Thyroid Disord., vol. 31, no. 2, pp. 213–224, Mar. 2017, doi: 10.1016/j.beem.2017.04.011.
A. Bizhanova and P. Kopp, “Genetics and phenomics of Pendred syndrome,” Spec. Issue Genet. Thyroid Dis., vol. 322, no. 1, pp. 83–90, Jun. 2010, doi: 10.1016/j.mce.2010.03.006.
J. P. Taylor, R. A. Metcalfe, P. F. Watson, A. P. Weetman, and R. C. Trembath, “Mutations of the PDS Gene, Encoding Pendrin, Are Associated with Protein Mislocalization and Loss of Iodide Efflux: Implications for Thyroid Dysfunction in Pendred Syndrome,” J. Clin. Endocrinol. Metab., vol. 87, no. 4, pp. 1778–1784, Apr. 2002, doi: 10.1210/jcem.87.4.8435.
A. Pera et al., “A mutational analysis of the SLC26A4 gene in Spanish hearing-impaired families provides new insights into the genetic causes of Pendred syndrome and DFNB4 hearing loss.,” Eur. J. Hum. Genet., vol. 16, no. 8, pp. 888–896, Aug. 2008, doi: 10.1038/ejhg.2008.30.
T. Yang et al., “Mutations of KCNJ10 Together with Mutations of SLC26A4 Cause Digenic Nonsyndromic Hearing Loss Associated with Enlarged Vestibular Aqueduct Syndrome,” Am. J. Hum. Genet., vol. 84, no. 5, pp. 651–657, May 2009, doi: 10.1016/j.ajhg.2009.04.014.
D A Scott, R Wang, T M Kreman, V C Sheffield, and L P Karniski, “The Pendred syndrome gene encodes a chloride-iodide transport protein,” Apr. 1999, doi: 10.1038/7783.
Philine Wangemann, Kazuhiro Nakaya, Tao Wu, and Rajanikanth J Maganti, “Loss of cochlear HCO−3 secretion causes deafness via endolymphatic acidification and inhibition of Ca2+ reabsorption in a Pendred syndrome mouse model,” Feb. 2007, doi: 10.1152/ajprenal.00487.2006.
Byung Yoon Choi, Hyoung-Mi Kim, Taku Ito, and Kyu-Yup Lee, “Mouse model of enlarged vestibular aqueducts defines temporal requirement of Slc26a4 expression for hearing acquisition,” Nov. 2011, doi: 10.1172/JCI59353.
Vincent Couloigner, Marie Teixeira, Olivier Sterkers, Helge Rask-Andersen, and Evelyne Ferrary, “The endolymphatic sac: its roles in the inner ear,” Med Sci Paris, [Online]. Available: https://www.medecinesciences.org/en/articles/medsci/full_html/2004/03/medsci2004203p304/medsci2004203p304.html
A. L.-Y. Pang, M. M. Martin, A. L. A. Martin, and W.-Y. Chan, “Chapter 22 - Molecular Basis of Diseases of the Endocrine System,” in Molecular Pathology, W. B. Coleman and G. J. Tsongalis, Eds., San Diego: Academic Press, 2009, pp. 435–463. doi: 10.1016/B978-0-12-374419-7.00022-6.
S. Albert et al., “SLC26A4 gene is frequently involved in nonsyndromic hearing impairment with enlarged vestibular aqueduct in Caucasian populations,” Eur. J. Hum. Genet., vol. 14, no. 6, pp. 773–779, Jun. 2006, doi: 10.1038/sj.ejhg.5201611.
G. R. FRASER, “Association of congenital deafness with goitre (Pendred’s syndrome): A study of 207 families,” Ann. Hum. Genet., vol. 28, no. 1–3, pp. 201–250, Sep. 1964, doi: 10.1111/j.1469-1809.1964.tb00479.x.
D A Scott, R Wang, T M Kreman, and M Andrews, “Functional differences of the PDS gene product are associated with phenotypic variation in patients with Pendred syndrome and non-syndromic hearing loss (DFNB4),” Jul. 2000, doi: 10.1093/hmg/9.11.1709.
Taku Ito, Julie Muskett, Parna Chattaraj, Kyu-Yup Lee, Christopher Zalewski, and Kelly King, “SLC26A4 mutation testing for hearing loss associated with enlargement of the vestibular aqueduct,” May 2015, doi: 10.5319/wjo.v3.i2.26.
S Pyror, A C Madeo, J C Reynolds, N J Sarlis, and K S Arnos, “SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities,” Feb. 2005, doi: 10.1136/jmg.2004.024208.
Anne C. Madeo, Ani Manichaikul, James C. Reynolds, and Nicholas J. Sarlis, “Evaluation of the Thyroid in Patients With Hearing Loss and Enlarged Vestibular Aqueducts,” Sep. 2010, doi: 10.1001/archoto.2009.66.
F. Forli, F. Lazzerini, G. Auletta, and L. Bruschini, “Enlarged vestibular aqueduct and Mondini Malformation: audiological, clinical, radiologic and genetic features,” Sep. 2020, doi: 10.1007/s00405-020-06333-9.
Hyoung-Mi Kim and Philine Wangemann, “Epithelial Cell Stretching and Luminal Acidification Lead to a Retarded Development of Stria Vascularis and Deafness in Mice Lacking Pendrin,” Mar. 2011, doi: 10.1371/journal.pone.0017949.
L. A. Everett et al., “Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome,” Hum. Mol. Genet., vol. 10, no. 2, pp. 153–161, Jan. 2001, doi: 10.1093/hmg/10.2.153.
Ruchira Singh and Philine Wangemann, “Free radical stress-mediated loss of Kcnj10 protein expression in stria vascularis contributes to deafness in Pendred syndrome mouse model,” Apr. 2015.
Ines E. Royaux, Inna A Belyantseva, Tao Wu, and Bechara Kachar, “Localization and Functional Studies of Pendrin in the Mouse Inner Ear Provide Insight About the Etiology of Deafness in Pendred Syndrome,” Sep. 2003, doi: 10.1007/s10162-002-3052-4.
Philine Wangemann, Hyoung-Mi Kim, Sara Billings, and Kazuhiro Nakaya, “Developmental delays consistent with cochlear hypothyroidism contribute to failure to develop hearing in mice lacking Slc26a4/pendrin expression,” Aug. 2009, doi: 10.1152/ajprenal.00011.2009.
Hiroaki Suzuki, Aki Oshima, Koji Tsukamoto, and Satoko Abe, “Clinical characteristics and genotype-phenotype correlation of hearing loss patients with SLC26A4 mutations,” Dec. 2007, doi: 10.1080/00016480701258739.
Kelly King et al., “SLC26A4 genotype, but not cochlear radiologic structure, is correlated with hearing loss in ears with an enlarged vestibular aqueduct (EVA),” Feb. 2011, doi: 10.1002/lary.20722.
Colm Madden, Mark Halsted, Jareen Meinzen-Derr, Dianna Bardo, Mark Boston, and Ellis Arjmand, “The influence of mutations in the SLC26A4 gene on the temporal bone in a population with enlarged vestibular aqueduct,” Feb. 2007, doi: 10.1001/archotol.133.2.162.
A J Griffith, A Arts, C Downs, and J W Innis, “Familial large vestibular aqueduct syndrome,” Aug. 1996, doi: 10.1097/00005537-199608000-00009.
Mengnan Li, Shin-Ya Nishio, Chie Naruse, and Meghan Riddell, “Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome,” Mar. 2020, doi: 10.1038/s41467-020-15198-9.
X. He, S. Zhao, L. Shi, Y. Lu, Y. Yang, and X. Zhang, “Compound heterozygous variants of the SLC26A4 gene in a Chinese family with enlarged vestibular aqueducts,” BMC Med. Genomics, vol. 15, no. 1, p. 152, Jul. 2022, doi: 10.1186/s12920-022-01271-3.
Q.-J. Wang et al., “A distinct spectrum of SLC26A4 mutations in patients with enlarged vestibular aqueduct in China,” Clin. Genet., vol. 72, no. 3, pp. 245–254, Sep. 2007, doi: 10.1111/j.1399-0004.2007.00862.x.
C. Wen et al., “Mutation analysis of the SLC26A4 gene in three Chinese families,” Biosci. Trends, vol. 13, no. 5, pp. 441–447, 2019, doi: 10.5582/bst.2019.01282.
K. Honda and A. J. Griffith, “Genetic architecture and phenotypic landscape of SLC26A4-related hearing loss,” Hum. Genet., vol. 141, no. 3, pp. 455–464, Apr. 2022, doi: 10.1007/s00439-021-02311-1.
Steven Raft, Leonardo R Andrade, Dongmei Shao, and Haruhiko Akiyama, “Ephrin-B2 governs morphogenesis of endolymphatic sac and duct epithelia in the mouse inner ear,” Feb. 2014, doi: 10.1016/j.ydbio.2014.02.019.
Lynn M. Pique, Marie-Luise Brennan, Colin J. Davidson, and Frederick Schaefer, “Mutation analysis of the SLC26A4, FOXI1 and KCNJ10 genes in individuals with congenital hearing loss,” May 2014, doi: 10.7717/peerj.384.
Malin Hulander, Amy E Kiernan, Sandro Rodrigo Blomqvist, and Peter Carlsson, “Lack of pendrin expression leads to deafness and expansion of the endolymphatic compartment in inner ears of Foxi1 null mutant mice,” May 2003, doi: 10.1242/dev.00376.
Tao Yang, Hilmar Vidarsson, Sandra Rodrigo-Blomqvist, Sally S Rosengren, Sven Enerback, and Richard J H Smith, “Transcriptional Control of SLC26A4 Is Involved in Pendred Syndrome and Nonsyndromic Enlargement of Vestibular Aqueduct (DFNB4),” Apr. 2007, doi: 10.1086/518314.
Chen-Chi Wu, “Phenotypic analyses and mutation screening of the SLC26A4 and FOXI1 genes in 101 Taiwanese families with bilateral nonsyndromic enlarged vestibular aqueduct (DFNB4) or Pendred syndrome,” Aug. 2009.
Stephen Mercer, Patricia Mutton, and Hans-Henrik M Dahl, “Identification of SLC26A4 mutations in patients with hearing loss and enlarged vestibular aqueduct using high-resolution melting curve analysis,” Mar. 2011, doi: 10.1089/gtmb.2010.0177.
Valentina Cirello, Claudia Bazzinni, Valeria Vezzoli, and Marina Muzza, “Molecular and functional studies of 4 candidate loci in Pendred syndrome and nonsyndromic hearing loss,” Jan. 2012, doi: 10.1016/j.mce.2012.01.013.
R Lai, P Hu, F Zhu, and G Zhu, “Genetic diagnosis and cochlear implantation for patients with nonsyndromic hearing loss and enlarged vestibular aqueduct,” Apr. 2012, doi: 10.1017/S002221511100346X.
Kaitian Chen, Xianren Wang, Liang Sun, and Hongyan Jian, “Screening of SLC26A4, FOXI1, KCNJ10, and GJB2 in bilateral deafness patients with inner ear malformation,” Mar. 2012, doi: 10.1177/0194599812439670.
Yongchuan Chai, Zhiwu Huang, Zheng Tao, and Xiaohua Li, “Molecular etiology of hearing impairment associated with nonsyndromic enlarged vestibular aqueduct in East China,” Aug. 2013, doi: 10.1002/ajmg.a.36068.
Philine Wangemann, blah, and blah, “Loss of KCNJ10 protein expression abolishes endocochlear potential and causes deafness in Pendred syndrome mouse model,” Aug. 2004.
Satoko Abe, Shin-ichi Usami, D M Hoover, and E Cohn, “Fluctuating sensorineural hearing loss associated with enlarged vestibular aqueduct maps to 7q31, the region containing the pendred gene,” Feb. 1999, doi: https://doi.org/10.1002/(SICI)1096-8628(19990212)82:4<322::AID-AJMG9>3.0.CO;2-0.
Serafino Garella and Bruce S. Chang, “Hemodialysis-Associated Hypoxemia,” Oct. 2008, doi: 10.1159/000166825.
Ont Health Technol Assess Ser., “Bilateral Cochlear Implantation: A Health Technology Assessment.” Oct. 24, 2018.
Marc K Bassim, Emily Buss, Marcia S Clark, and Karen A Kolln, “MED-EL Combi40+ cochlear implantation in adults,” Sep. 2005, doi: 10.1097/01.mlg.0000171023.72680.95.
F. Forli, G. Turchetti, G. Giuntini, and S. Bellelli, “Cochlear implant in prelingually deafened oralist adults: speech perception outcomes, subjective benefits and quality of life improvement,” Oct. 2017, doi: 10.14639/0392-100X-1493.
Theodore McRackan, Michael Bauschard, Jonathan L Hatch, and Emily Franko-Tobin, “Meta-analysis of cochlear implantation outcomes evaluated with general health-related patient-reported outcome measures,” Jan. 2018, doi: 10.1097/MAO.0000000000001620.
Che-Ming Wu, Hui-Chen Ko, Yung-Ting Tsou, and Yin-Hung Lin, “Long-Term Cochlear Implant Outcomes in Children with GJB2 and SLC26A4 Mutations,” 2015, doi: 10.1371/journal.pone.0138575.
Berat Demir, Sidika Cesur, Sefa Incaz, Nilufer Deniz Alberalar, Ayca Ciprut, and Caglar Batman, “The effect of canal diameter on audiologic results in patients with cochlear implantation with large vestibular aqueduct syndrome,” Dec. 2019, doi: 10.1007/s00405-019-05764-3.
Hui-Chen Ko et al., “Timing of Surgical Intervention with Cochlear Implant in Patients with Large Vestibular Aqueduct Syndrome,” 2013, doi: 10.1371/journal.pone.0081568.
J W I van Nierop, W J Huinck, R J E Pennings, and R J C Admiraal, “Patients with Pendred syndrome: is cochlear implantation beneficial?,” Feb. 2016, doi: 10.1111/coa.12532.
Chen-Chi Wu, Tien-Chen Liu, Shih-Hao Wang, and Chuan-Jen Hsu, “Genetic characteristics in children with cochlear implants and the corresponding auditory performance,” May 2011, doi: 10.1002/lary.21751.
Joo Hyun Park, Ah Reum Kim, Jin Hee Han, and Seong Dong Kim, “Outcome of Cochlear Implantation in Prelingually Deafened Children According to Molecular Genetic Etiology,” Oct. 2017, doi: 10.1097/AUD.0000000000000437.
Maxime Gratacap, Briac Thierry, Isabelle Rouillon, Sandrine Marlin, Noel Garabedien, and Natalie Loundon, “Pediatric cochlear implantation in residual hearing candidates,” Jun. 2015, doi: 10.1177/0003489414566121.
Kasper Sandager Mikkelsen, Lisbeth Tranebjærg, and Kristianna Mey, “Cochlear implantation in a 10-year old boy with Pendred syndrome and extremely enlarged endolymphatic sacs,” Mar. 2019.
Levent Sennaroglu, “Cochlear implantation in inner ear malformations--a review article,” Mar. 2010.
National Institute on Deafness and Other Communication Disorders, “Enlarged Vestibular Aqueducts and Childhood Hearing Loss.” [Online]. Available: https://www.nidcd.nih.gov/health/enlarged-vestibular-aqueducts-and-childhood-hearing-loss#:~:text=Research%20suggests%20that%20most%20children,inside%20the%20cochlea)%20have%20EVA.
T. C. Hain and M. Uddin, “Pharmacological Treatment of Vertigo,” CNS Drugs, vol. 17, no. 2, pp. 85–100, Feb. 2003, doi: 10.2165/00023210-200317020-00002.
Layal Chaker, Antonio C Bianco, Jacqueline Jonklaas, and Robin P Peeters, “Hypothyroidism,” Mar. 2017, doi: 10.1016/S0140-6736(17)30703-1.
Jacqueline Jonklaas, Antonio C. Bianco, Andrew J. Bauer, and Kenneth D. Burman, “Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement,” Dec. 2014, doi: 10.1089/thy.2014.0028.
Simon H.S. Pearce, Georg Brabant, Leonidas H. Duntas, and Fabio Monzani, “2013 ETA Guideline: Management of Subclinical Hypothyroidism,” Nov. 2013, doi: 10.1159/000356507.
Annemieke Roos, Suzanne P Linn-Rasker, Ron T van Domburg, Jan P Tijssen, and Arie Berghout, “The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial,” Aug. 2005, doi: 10.1001/archinte.165.15.1714.
Peter N Taylor, Ahmed Iqbal, and Caroline Minassian, “Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study,” Jan. 2014, doi: 10.1001/jamainternmed.2013.11312.
Lily L. Somwaru, Alice M Arnold, Neha Joshi, and Linda P Fried, “High Frequency of and Factors Associated with Thyroid Hormone Over-Replacement and Under-Replacement in Men and Women Aged 65 and Over,” Jan. 2009, doi: 10.1210/jc.2008-1696.
Damiano Gullo, Adele Latina, Francesco Frasca, and Rosario Le Moli, “Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients,” Aug. 2011, doi: 10.1371/journal.pone.0022552.
Mitsuru Ito et al., “TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy,” Sep. 2012, doi: 10.1530/EJE-11-1029.
Jacqueline Jonklaas, “Triiodothyronine levels in athyreotic individuals during levothyroxine therapy,” Feb. 2008.
Birte Nygaard, Ebbe Winther Jensen, Jan Kvetny, and Anne Jarløv, “Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study,” Aug. 2009, doi: 10.1530/EJE-09-0542.
John P Walsh, Lauren Shiels, Ee Mun Lim, and Chotoo I Bhagat, “Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism,” Oct. 2003, doi: 10.1210/jc.2003-030249.
Héctor F Escobar-Morreale, José I. Botella-Carretero, and Manuel Cómez-Bueno, “Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone,” Mar. 2005, doi: 10.7326/0003-4819-142-6-200503150-00007.
Downloads
Posted
Categories
License
Copyright (c) 2024 Vivian Kao
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.